TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-small cell lung cancer stage IB - IIIA, complete resection with mediastinal lymph node dissection~* ECOG status 0-1~* \>14 and \<56 days since resection~Exclusion Criteria:~* Prior chemotherapy and/or radiation therapy for lung cancer~* Peripheral neuropathy \> grade 1~* Concurrent other malignancies, other than basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix~* Medical condition that will not permit treatment or follow up according to the protocol~* Prior treatment with docetaxel or carboplatin~* Hypersensitivity to polysorbate 80, platinum-containing compounds or mannitol~* Treatment with other investigational anti-cancer drugs within 30 days of registration~* Pregnant or nursing women~* HIV-positive patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin Area Under the Curve 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Females must be post-menopausal for more than 2 years or surgically sterile or practicing specific forms of birth control~2. Chronic hepatitis C, genotype 1-infection (HCV RNA level greater than 1,000 IU/mL at screening)~3. HCV genotype 1 infection per screening laboratory result~Exclusion Criteria:~1. Use of contraindicated medications within 2 weeks of dosing~2. Abnormal laboratory tests~3. Positive hepatitis B surface antigen and anti-Human Immunodeficiency Virus Antibody~4. History of solid organ transplant, clinical evidence of Child-Pugh B or C classification or clinical history of liver decompensation~5. Presence of hepatocellular carcinoma at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV) (Type: EXPERIMENTAL): Participants with HCV GT1b without cirrhosis received the 3-DAA (ABT-450/ritonavir/ABT-267 and ABT-333) regimen: two 75 mg ABT-450/50 mg ritonavir/12.5 mg ABT-267 tablets taken orally every morning (QD) and one ABT-333 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis and those with HCV GT1b with cirrhosis received the 3-DAA regimen and weight-based ribavirin (RBV; 1000 to 1200 mg divided twice daily per local label) for 12 weeks. Participants with HCV GT1a with cirrhosis received the 3-DAA regimen and weight-based RBV per local label for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with chronic kidney disease (CKD) stage 3 (creatinine clearance \[CrCl\]/ glomerular filtration rate \[GFR\] 30 to 59 milliliter per minutes per 1.73 meter square \[mL/min/1.73m\^2\]) or Stage 4 (CrCl/GFR 15-29 mL/min/1.73m\^2) who did not require dialysis. CrCl/GFR was estimated with the Cockcroft-Gault equation or the abbreviated Modification of Diet in Renal Disease (MDRD) equation~* Anemia defined as baseline Hb concentration less than (\<) 10.5 gram per deciliter (g/dL)~Exclusion Criteria:~* Previous therapy with any ESA within 12 weeks prior to screening~* Renal allograft in place~* Immunosuppressive therapy in the 12 weeks prior to screening~* Overt gastrointestinal bleeding and red blood cells (RBC) transfusions within 8 weeks before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mircera (Type: EXPERIMENTAL): Participants will receive Mircera (Methoxy polyethylene glycol-epoetin beta), administered subcutaneously (SC) at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.
- Darbepoetin Alfa (Type: ACTIVE_COMPARATOR): Participants will receive darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants with type 1 diabetes~* Body mass index (BMI) between 18.5 and 30.0 kilograms per square meter, inclusive~* Hemoglobin A1c (HbA1c) less than or equal to 8.5 percent (%)~* Using CSII and stable insulin regimen for at least 3 months prior to inclusion into the trial~Exclusion Criteria:~* Known or suspected hypersensitivity to investigational medical product(s) or related products~* Receipt of any medicinal product in clinical development within 30 days or at least 5 half-lives of the related substances and their metabolites (whichever is longer) before randomization in this trial~* Known slowing of gastric emptying and or gastrointestinal surgery that, in the opinion of the investigator, might change gastrointestinal motility and food absorption~* Proliferative retinopathy or maculopathy as judged by the Investigator based on a recent (less than 1.5 years) ophthalmologic examination~* Widespread subcutaneous lipodystrophy in the abdomen~* Current use of any glucose-lowering agents other than insulin within 3 months prior to screening~* Chronic or recent use of corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 100 U/mL LY900014 (Type: EXPERIMENTAL): 100 units per milliliter (U/mL) LY900014 administered by continuous subcutaneous insulin infusion (CSII) in one of two study periods.
- 100 U/mL Insulin Lispro (Humalog) (Type: ACTIVE_COMPARATOR): 100 U/mL Insulin Lispro (Humalog) administered by CSII in one of two study periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Living in one of the study villages~* Aged 2 years and above~* Able and willing to provide informed consent~Exclusion Criteria:~* Signs of active leprosy (\*)~* Signs of active pulmonary tuberculosis (cough ≥2 weeks duration) (\*)~* Having received Rifampicin within the last 24 months (\*)~(\*) These people may still be included for yearly leprosy screening, but will be excluded to receive PEP

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- No PEP (Type: NO_INTERVENTION): No PEP will be distributed
- Household PEP (Type: OTHER): PEP will be given to all household contacts of an incident leprosy patient
- PEP 100m (Type: EXPERIMENTAL): PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient.
- PEP 100m + positive for anti-PGL-I IgM Ab (Type: OTHER): PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient who test positive in the UCP-LFA detecting anti-M. leprae PGL-I IgM Ab in fingerstick blood (anti-PGL-I)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Successfully completed the parent study 990120~* Agreed to use highly effective (in the opinion of the principal investigator) contraceptive measures throughout the study~* Were able to comprehend and were willing to give written informed consent for participation in the study~Exclusion Criteria:~* Pregnant or breast-feeding~* Had a psychiatric disorder that interfered with the understanding and giving of informed consent or compliance with protocol requirements~* Had any other condition that reduced the chance of obtaining data (eg, known poor compliance)~* Participating in another investigational study at the time of study entry~* Had any unstable medical condition, defined as having been hospitalized within 28 days before day 1, or otherwise unstable in the judgment of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cinacalcet (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* positive attention-deficit/hyperactivity disorder (ADHD) diagnosis with at least moderate severity~* male or female 18 to 30 years of age~* must be able to swallow capsules~* must be able to communicate effectively in English~* must not have cognitive impairment~* be reliable to keep appointments for clinic visits and all related tests~Exclusion Criteria:~* patients diagnosed with obsessive-compulsive disorder, bipolar affective disorder, or psychosis~* females who are pregnant or breastfeeding~* patients with dementia or traumatic brain injury~* patients with a history of severe allergy to atomoxetine~* have untreated hypertension or thyroid problem~* have serious medical illness including any heart, liver, kidney, respiratory, blood, endocrine, or neuromuscular diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 to 68 years of age~* Confirmed diagnosis of Multiple Sclerosis~* Clinical history of pseudobulbar affect~Exclusion Criteria:~* Sensitivity to quinidine or opiate drugs~* Recent diagnosed within 2 months with Multiple Sclerosis~* Patient on anti-depressants~* Patient with liver or kidney disease~* Patient with hypotension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is an Asian Indian male between 18 to 45 years of age~* Subject is in good health~* Subject is a nonsmoker or has not used nicotine-containing products for six months~* Subject is willing to avoid strenuous activity~Exclusion Criteria:~* Subject has a history of stroke, seizures, or major neurological disorders~* Subject has irritable bowel disease or recurrent nausea, vomiting, diarrhea, or abdominal pain~* Subject has a history of high blood pressure requiring treatment~* Subject has history of cancer~* Subject has a history of diabetes

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Sitagliptin/Sitagliptin/Placebo (Type: EXPERIMENTAL): Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
- Sitagliptin/Placebo/Sitaglipitin (Type: EXPERIMENTAL): Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
- Placebo/Sitagliptin/Sitagliptin (Type: EXPERIMENTAL): Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of an infection consistent with complicated skin and skin structure infections.~Exclusion Criteria:~* Known or suspected hypersensitivity to any study medication or other related anti-infective medication~* Any known or suspected condition or concurrent treatment contraindicated by the prescribing information~* Previous enrollment in this study~* Treatment with any investigational drug within 30 days before enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vancomycin plus Ceftazidime (Type: ACTIVE_COMPARATOR): Vancomycin 1g q12h as 1h infusions plus Ceftazidime 1g q8h in 2h-infusions, 7-14d
- Ceftobiprole medocaril (Type: EXPERIMENTAL): Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males between 18 and 65 years of age (inclusive)~* Hemizygous for Fabry disease~* Had a confirmed diagnosis of Fabry disease with a documented missense gene mutation (individual or familial)~* Had enhanceable enzyme activity based on in vitro tests~* Had documented evidence of cardiac and/or renal dysfunction (for example, abnormal electrocardiogram (ECG), left ventricular hypertrophy, renal insufficiency)~* Were previously untreated by enzyme replacement therapy (ERT) or substrate depletion for Fabry disease, or if ERT or other specific treatment for Fabry disease was administered, were able to stop ERT for at least 30 weeks.~* Were willing to undergo 2 kidney and 3 skin biopsies~* Agreed to be sexually abstinent or use a condom with spermicide when engaging in sexual activity during the course of the study and for a period of 30 days following completion of the study~* Were willing and able to sign an informed consent form~Exclusion Criteria:~* History of significant disease other than Fabry disease (for example, end-stage renal disease; Class III or IV heart disease \[per the New York Heart Association classification\]; current diagnosis of cancer, except for basal cell carcinoma of the skin; diabetes \[unless hemoglobin A1c ≤8\]; or neurological disease that would have impaired the participant's ability to participate in the study)~* History of organ transplant~* Serum creatinine \>176 millimole per deciliter on Day -2~* Screening 12-lead ECG demonstrating corrected QT interval \>450 milliseconds prior to dosing~* Taking a medication prohibited by the protocol: Fabrazyme® (agalsidase beta), Replagal™ (agalsidase alfa), Glyset® (miglitol), Zavesca® (miglustat), or any experimental therapy for any indication~* Participated in a previous clinical trial in the last 30 days~* Any other condition, which, in the opinion of the investigator, would jeopardize the safety of the participant or impact the validity of the study results

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Migalastat (Type: EXPERIMENTAL): Migalastat 150 milligrams (mg) was administered orally QOD during the 24-week treatment period and then during the optional 24-week extension period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PTE confirmed either by a high probability ventilation-perfusion lung scanning (V/Q scan) or by CTPA.~* massive PTE patients with haemodynamic instability and/or cardiogenic shock~* Anatomic obstruction more than 2 lobes on CTPA and/or defect more than 7 segments on V/Q scan with evidence of right ventricular dysfunction (RVD) and pulmonary hypertension on echocardiography~* Symptoms within 15 days~* Written informed consent was obtained from all the patients before randomization~Exclusion Criteria:~* Received parenteral heparin for more than 72 hours~* Known allergic to urokinase~* Thrombolytic contraindications such as:~  1. active bleeding or spontaneous intracranial hemorrhage;~ 2. major surgery, organ biopsy or recent puncture of a non-compressible vessel less than 10 days;~ 3. cerebral arterial thrombosis within 2 months;~ 4. gastro-intestinal bleeding within 10 days;~ 5. major trauma within the past 15 days;~ 6. neurosurgery or ophthalmologic operation with 30 days;~ 7. uncontrolled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 110 mmHg);~ 8. recent external cardiac resuscitation manoeuvres;~ 9. platelet count \< 100 000/mm3 at admission;~ 10. pregnancy, puerperium or lactation with 2 weeks;~ 11. infectious pericarditis or endocarditis;~ 12. severe hepatic and kidney dysfunction;~ 13. hemorrhagic retinopathy due to diabetes;~ 14. a known bleeding disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): UK-12h group
- Group 2 (Type: EXPERIMENTAL): UK-2h group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of ProQuad® rHA in Infants (V221-037)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subject of either gender,~* Age from 12 to 22 months,~* Negative clinical history of infection with measles, mumps, rubella, varicella or zoster,~* Informed consent form signed by the parent(s) or by legal representative~* Parent(s) or legal representative able to attend all schedule visits with the subject and to understand and comply with the study procedures~Exclusion Criteria:~* Recent (≤ 3 days) history of febrile illness~* Prior receipt of measles, mumps, rubella and/or varicella vaccination, either alone or in any combination~* Recent (≤ 30 days) exposure to measles, mumps, rubella, varicella or zoster~* Prior known sensitivity/allergy to any component of the vaccine~* Severe chronic disease,~* Blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic system~* Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection~* Humoral or cellular immunodeficiency,~* Current immunosuppressive therapy~* Family history of congenital or hereditary immunodeficiency~* Hereditary problems of fructose intolerance~* Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition,~* Known active tuberculosis~* Recent (≤ 2 days) tuberculin test or scheduled tuberculin test through Visit 3~* Receipt of immunoglobulins or blood-derived products in the past 150 days~* Receipt of an inactivated vaccine in the past 14 days~* Receipt of a live vaccine in the past 28 days~* Any medical condition which, in the opinion of the investigator, might interfere with the evaluation of study objectives~* Participation in another clinical study in the past 30 days

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 22 Months
- Healthy Volunteers: t

Study Arms:
- ProQuad® (Type: EXPERIMENTAL): Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete